| 764068 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
677 Reverse abscopal effect: intertumoral heterogeneity suppresses systemic CD8 T cell-mediated antitumor immunity and confers PD-1 inhibitor resistance in synchronous melanoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.677 |
Qin Shuyang, Han Booyeon, Chacon Alexander, Melucci Alexa, Williams Alyssa, Jewell Rachel, Kim Minsoo, Linehan David, Gerber Scott, Prieto Peter |
| 764067 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
675 Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.675 |
Jain Michael, Ziccheddu Bachisio, Coughlin Caroline, Faramand Rawan, Griswold Anthony, Reid Kayla, Landgren Ola, Locke Frederick, Maura Francesco, Davila Marco, Schatz Jonathan |
| 764066 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
674 IL-27 signaling drives a type 1 interferon-like gene expression program of immunoregulatory pathways associated with cancer progression |
2021-11-01 |
10.1136/jitc-2021-sitc2021.674 |
Hill Jonathan, Moodley Devapregasan, Hua Jing, White Kerry, Miller Christine, Koseoglu Secil, Masia Ricard, Lee Benjamin, Palombella Vito |
| 764065 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
673 (Re-) Solving the biology of colorectal cancer onset and progression to improve treatment and prevention |
2021-11-01 |
10.1136/jitc-2021-sitc2021.673 |
Roelands Jessica, Ploeg Manon van der, Dang Hao, Hawinkels Lukas, Morreau Hans, Miranda Noel de |
| 764064 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
672 The effect of chemoradiotherapy and tumor histology on the immune contexture of tumor-draining lymph nodes in NSCLC |
2021-11-01 |
10.1136/jitc-2021-sitc2021.672 |
Fransen Marieke, Schneiders Famke, Kandiah Vinitha, Radonic Teodora, Bahce Idris, Dickhoff Chris, Gruijl Tanja de |
| 764063 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.520 |
Robbrecht Debbie, Jean-Jacques Grob, Bechter Oliver, Santoro Armando, Doger Bernard, Borbath Ivan, Marcus Butler, Tina Cheng, Martin Patricia, Jaafar Bennouna, Nicola Massimo Di, Curigliano Giuseppe, Ryu Min-Hee, -Vida Alejo Rodriguez, Schadendof Dirk, Garralda Elena, Abbadessa Giovanni, Demers Brigitte, Amrate Amele, Lin Tun Tun, Brahmachary Manisha, Lee Joon Sange, Theilhaber Joachim, Pomponio Rob, Wang Rui |
| 764062 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
519 A first-in-human, multicenter, phase 1/2, open-label study of XTX101 in patients with advanced solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.519 |
Powderly John, Norman Teleen, Duncan Meghan, Huber Martin, O’Neil Jennifer, Patel Ekta, Vandross Andrae |
| 764061 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
515 A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours |
2021-11-01 |
10.1136/jitc-2021-sitc2021.515 |
Plummer Ruth, Sodergren Mikael, Pinato David, Sarker Debashis, Reebye Vikash, Spalding Duncan, Raulf Nina, Sinigaglia Laura, Talbot Thomas, Cortellini Alessio, D’Alessio Antonio, Tchakov Ilian, Habib Robert, Rossi John, Habib Nagy |
| 764060 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
510 SO-C101, a high-affinity IL-15Rbg agonist, induces safe and potent anti-tumor immune activities in patients with solid tumors and supports further clinical investigations |
2021-11-01 |
10.1136/jitc-2021-sitc2021.510 |
Palová Lenka |
| 764059 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.509 |
Naing Aung, Callahan Margaret, Costello Brian, Bifulco Carlo, Hall Evan, Hansen Aaron, Long Georgina, Joshua Anthony, Shankles Brooke, Ulge Umut, Ulge Umut, Weickhardt Andrew |
